Remove 2022 Remove HIV Treatment and Prevention Agents Remove Packaging
article thumbnail

Top 20 RNAi Therapeutic Companies Based on 2022 R&D Expenditure

PharmaShots

In 2022, the global market size of RNAi drug delivery was valued at $69.2B. Even though the company manages to generate a considerable revenue of $21.18M in 2022 through its collaborative agreements, Silence Therapeutics still waiting for the approval of its products. R&D Expenditure: $85.1M R&D Expenditure: $437.9M

article thumbnail

Oral COVID Agents

Pharmacy Friday Pearls

18 years Administration Oral Oral Oral PK/PD MOA: Nirmatrelvir – inhibitor of the SARS-CoV-2 main protease Prevents viral replicationRitonavir is a CYP3A inhibitor included to increase nirmatrelvir plasma levelsRitonavir alone has NO activity against SARS-CoV-2 Time to peak: Nirmatrelvir: 3 hrs & Ritonavir: 3.98 Introduction.

article thumbnail

Contents

RX Note

Soft Contact Lenses - A basic overview Red Eye - Discussion on few possible conditions Styes - Warm compresses are the mainstay of treatment Eye Floaters - It is not often treated, except in severe cases.